Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518150 | 0.91 | DYRK3 (0.40) | ALDH1A1KDM4EHPGDDYRK3CSNK1E | |
| SCHEMBL3519468 | 0.82 | USP2 (0.49) | ALDH1A1KDM4EHPGDCSNK1ECLK1 | |
| SCHEMBL12085466 | 0.79 | KDM4E (0.46) | ALDH1A1KDM4EHPGDEGFRNR1H2 | |
| SCHEMBL9893434 | 0.74 | BRD4 (0.39) | ALDH1A1DYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL3516991 | 0.72 | CNR1 (0.42) | DYRK3CSNK1ECLK1CLK2CLK3 | |
| SCHEMBL3520343 | 0.72 | USP2 (0.53) | ALDH1A1KDM4EHPGDCSNK1ECLK1 | |
| SCHEMBL3519290 | 0.71 | CNR1 (0.41) | ALDH1A1DYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL3516032 | 0.70 | GAA (0.41) | ALDH1A1DYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL10336238 | 0.69 | F2 (0.42) | ALDH1A1KDM4EHPGDUSP2GAA | |
| SCHEMBL3521032 | 0.68 | CNR1 (0.46) | ALDH1A1DYRK3CSNK1ECLK1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254873-B1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8664217-B2 | Benzodiazepine compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20130040941-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. | 2013-02-14 | — | — | US | disclosed |
| US-8338406-B2 | Benzodiazepine compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20100331317-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331317-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | KCNA5, KCNA1, KCNAB1 | ALDH1A1 1848/4885KDM4E 1086/4885HPGD 2156/4885 |
| US-20130040941-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | KCNA5, KCNA1, KCNAB1 | ALDH1A1 1848/4885KDM4E 1086/4885HPGD 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.